Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

(2018) Nan Chen et al.   CURRENT OPINION IN IMMUNOLOGY

NKG2D and its ligands in cancer

(2018) Payal Dhar et al.   CURRENT OPINION IN IMMUNOLOGY

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

(2018) Jian Li et al.   Journal of Hematology & Oncology

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA + Metastatic Colorectal Cancers

(2017) Chengcheng Zhang et al.   MOLECULAR THERAPY

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer

(2017) Somala Mohammed et al.   MOLECULAR THERAPY

Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor

(2017) Vasyl Eisenberg et al.   Frontiers in Immunology

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors

(2017) Christine Koch et al.   Frontiers in Immunology

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment

(2017) Irene Scarfò et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma

(2016) N. J. Mason et al.   CLINICAL CANCER RESEARCH

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Gastric cancer

(2016) Eric Van Cutsem et al.   LANCET

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

(2016) Richard P. Junghans et al.   PROSTATE

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

(2016) Fengtao You et al.   Science China-Life Sciences

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer

(2014) M. Javle et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment

(2014) Gregory L Beatty et al.   OncoImmunology

NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors

(2013) Paul Spear et al.   IMMUNOLOGY AND CELL BIOLOGY

Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells

(2013) T. Zhang et al.   JOURNAL OF IMMUNOLOGY

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

(2013) James N. Kochenderfer et al.   Nature Reviews Clinical Oncology

The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells

(2012) Yifan Zhan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection

(2012) Manfred Lehner et al.   PLoS One

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

(2012) David E. Gilham et al.   TRENDS IN MOLECULAR MEDICINE

Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells

(2011) A Barber et al.   GENE THERAPY

Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence

(2011) Hiroteru Kamimura et al.   JOURNAL OF HEPATOLOGY

Trastuzumab for gastric cancer treatment

(2010) Tetsuji Fujita   LANCET

NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting

(2009) R. W. McGilvray et al.   CLINICAL CANCER RESEARCH

Chimeric NKG2D T Cells Require Both T Cell- and Host-Derived Cytokine Secretion and Perforin Expression to Increase Tumor Antigen Presentation and Systemic Immunity

(2009) A. Barber et al.   JOURNAL OF IMMUNOLOGY

Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment

(2009) A. Barber et al.   JOURNAL OF IMMUNOLOGY